Recent News

• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.09.2025 - Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
• 06.04.2025 - Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
• 05.13.2025 - Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
• 05.01.2025 - Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Recent Filings

• 06.09.2025 - 8-K Current report
• 05.28.2025 - 8-K Current report
• 05.21.2025 - 8-K Current report
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors